Skip to content
Triangle logo TriangleGet started
← Full study record

NCT06024174 · OUTCOME

Part 1a and 1b - Changes From Baseline in Pharmacodynamic Biomarker

A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors · Source last updated 2025-07-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Baseline and Cycle 1 Day 1 (Each cycle consist of 28 days)

What was measured

Blood samples were collected for assessing pharmacodynamic parameters.

Analysis population: All treated participants with available biomarker data. Participants were not enrolled in Part 1a and 1b arm, hence participants analyzed is 0. Prespecified to be collected for Part 1A and 1B only.

Groups in this outcome

Part 1A

Part 1A consist of dose escalation of BMS-986466 in combination with adagrasib in KRAS G12C-mutant NSCLC, PDAC, BTC, and CRC.

Part 1B

Part 1B was planned to evaluate the dose escalation of BMS-986466 in combination with adagrasib plus Cetuximab in KRAS G12C-mutant CRC.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part 1A0
Part 1B0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    units
    Participants
description
Blood samples were collected for assessing pharmacodynamic parameters.
groups
  1. description
    Part 1A consist of dose escalation of BMS-986466 in combination with adagrasib in KRAS G12C-mutant NSCLC, PDAC, BTC, and CRC.
    id
    OG000
    title
    Part 1A
  2. description
    Part 1B was planned to evaluate the dose escalation of BMS-986466 in combination with adagrasib plus Cetuximab in KRAS G12C-mutant CRC.
    id
    OG001
    title
    Part 1B
population Description
All treated participants with available biomarker data. Participants were not enrolled in Part 1a and 1b arm, hence participants analyzed is 0. Prespecified to be collected for Part 1A and 1B only.
reporting Status
POSTED
time Frame
Baseline and Cycle 1 Day 1 (Each cycle consist of 28 days)
title
Part 1a and 1b - Changes From Baseline in Pharmacodynamic Biomarker
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice